Company intelligence / Profile preview

Vyant Bio, Inc.

Cherry Hill, New Jersey, United States

Ownership: Private
Development stage: Preclinical

Overview

Vyant Bio focuses on drug discovery for complex neurodevelopmental and neurodegenerative disorders using innovative biology and data science. The company has recently delisted from Nasdaq and is pursuing strategic alternatives.

Therapeutic areas: Neurology
Modalities: Novel and repurposed therapeutics
Industry: Biotech

Drug pipeline

1 asset

VYNT-010037

Preclinical

Partnerships

Collaborations with leading pharmaceutical companies and academic institutions

Beyond the preview

Go deeper on Vyant Bio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vyant Bio, Inc..

Explore the full profile